AAA's cancer candidate Lutathera "first theranostic drug" to start PhIII
This article was originally published in Clinica
Executive Summary
French diagnostic/therapeutic company Advanced Accelerator Applications (AAA) has pushed its investigational cancer candidate Lutathera (177Lu-DOTA-Octreotate) into Phase III trials, after earlier clinical work suggesting that the drug can extend life expectancy by 3.5 years in a subset of gastro-entero pancreatic neuroendocrine tumour types.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.